In Brief: Faulding
Executive Summary
Faulding: U.S. sales for fiscal 1996 are up 14% to $100 mil., Faulding announces Sept. 2, "although an operating loss of $7.1 mil. was recorded." Loss reflects "establishment costs related to the injectables business, ongoing delays in the receipt of product approvals, the generic activities of brand companies and the increased level of price-based competition," company explains...